A complex of histamine/mouse gamma-globulin preferentially inhibits allergen-induced peritoneal accumulation of eosinophils, but not neutrophils, in mice.
A complex of histamine/human gamma-globulin (HhG) has been widely used in Japan for more than 25 years as a nonspecific hyposensitization drug in the treatment of allergic diseases. It has been reported that HhG decreases the number of eosinophils in the nasal secretions and peripheral blood of patients with allergy. In this study we used a mouse system to explore the possibility that HhG may actively inhibit the accumulation of eosinophils at inflammation sites. A complex of 0.15 microg of histamine dihydrochloride/12 mg of mouse gamma-globulin (HmG) was incubated for 2 hours in saline solution in the normal fashion for HhG. HmG at 50 to 150 mg/kg/day inhibited the peritoneal accumulation of eosinophils induced by ragweed pollen in BALB/c mice in a dose-dependent fashion when the HmG was administered subcutaneously six times during a 20-day sensitization period. The inhibitory effect of HmG on this eosinophil accumulation was significant at 24 and 48 hours after challenge, but HmG had no effect on neutrophil accumulation. Complexes of serotonin/mouse gamma-globulin (mgammaG), glutamine/mgammaG, and histamine dihydrochloride (His)/mouse albumin had no inhibitory effect when administered in the same way. The optimum combination ratio was between 0.15 microg of His/12 mg of mgammaG and 0.015 microg of His/12 mg of mgammaG for this eosinophil inhibition. Moreover, a 1- to 2-hour incubation period of His and mgammaG was needed to induce a plateau inhibition of the eosinophil accumulation. These results in mice suggest that HhG may actively inhibit allergen-induced eosinophil accumulation, which may be therapeutically useful in the treatment of allergic disease.
Yoshii
H
H
Department of Allergology, Institute of Bio-Active Science, Nippon Zoki Pharmaceutical Company, Hyogo, Japan.
Fukata-Yamazaki
Y
Y
Yamamoto
K
K
Yago
H
H
Yanagihara
Y
Y
Okudaira
H
H
D000485:Allergens / Q000276:immunology; D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D001202:Ascitic Fluid / Q000276:immunology / Q000473:pathology*; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D004338:Drug Combinations; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology*; D005260:Female; D006632:Histamine / Q000494:pharmacology* / Q000502:physiology; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D011058:Pollen / Q000276:immunology*; D012189:Retrospective Studies; D013997:Time Factors; D005719:gamma-Globulins / Q000494:pharmacology* / Q000502:physiology
D000485:Allergens; D018926:Anti-Allergic Agents; D004338:Drug Combinations; D005719:gamma-Globulins; C002114:Histaglobin; D006632:Histamine